S. Negoro

Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders

M. Fukuoka, K. Furuse, N. Masuda, 2005, Journal of Cancer Research and Clinical Oncology.

Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.

M. Fukuoka, N. Masuda, N. Yamamoto, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

M. Fukuoka, S. Kudoh, N. Yamamoto, 2006, British Journal of Cancer.

A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.

T. Mukohara, M. Fukuoka, S. Kudoh, 2005, Japanese journal of clinical oncology.

A Phase I intermittent dose-escalation trial of ZD1839 (IressaTM) in Japanese patients with solid malignant tumors

M. Fukuoka, S. Kudoh, N. Yoshimura, 2000 .

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.

M. Fukuoka, N. Yamamoto, H. Swaisland, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group trial (WJTOG9904)

M. Fukuoka, M. Takada, T. Satoh, 2005 .